What Delsym DM Treats: Main Uses and Benefits

Delsym DM is a supportive therapeutic option that contributes to easing the overall symptom load of specific respiratory symptoms, and is relevant for managing distressing manifestations that interfere with daily functioning. It is applied in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is appropriate.

The medication is commonly used across conditions presenting with acute episodes, such as cough associated with the common cold, influenza (flu), and minor throat or bronchial irritation. It is applied in contexts where this sustained irritation creates noticeable interference, and the primary therapeutic benefit is to provide temporary support that may assist with managing the constant urge to cough.

“It supports patients during difficult symptomatic episodes by contributing to a sense of stability when symptoms are more noticeable.”

Symptomatic relief over an extended period is supported, which is particularly relevant when acute cough manifestations interfere significantly with rest or sleep. This supports functional stability during symptomatic periods and helps manage challenging cough symptoms for both adults and appropriate pediatric patients experiencing temporary functional strain.

Quick Fact: Relief for Persistent Cough
Primary Target	Non-productive, dry cough
Clinical Context	Acute symptoms of cold or flu
Key Benefit	Supports comfort over time and rest

Regulatory References

1. Dextromethorphan MedlinePlus Drug Information

Who Can and Cannot Use Delsym DM?

Eligibility for Delsym DM is defined by specific population rules and contraindications strictly outlined in government regulatory labeling.

---

Absolute Non-Eligibility

Use of Delsym DM is contraindicated and explicitly prohibited for two primary populations:

• Individuals taking or who have taken a Monoamine Oxidase Inhibitor (MAOI) prescription drug within the last 14 days.
• Children under 4 years of age. The product is labeled "Do not use" for this age group.

Age-Related Eligibility

Age Group	Eligibility Status
Adults (12 years and over)	Approved for use
Children (4 to under 12 years)	Approved for use

---

Restricted or Conditional Use

Certain populations must consult a health professional before use, as use is restricted or conditional:

• Pregnant and breastfeeding individuals.
• Individuals with a chronic cough (e.g., associated with smoking, asthma, or emphysema).
• Individuals with a cough that produces excessive phlegm.

Delsym DM, which contains the active ingredient Dextromethorphan, has documented interactions that require patient awareness and healthcare provider oversight.

Contraindicated Combinations

Interacting Product Category	Constraint
Monoamine Oxidase Inhibitors (MAOIs)	Do not use this product with an MAOI or for 2 weeks after stopping an MAOI, due to the major risk of Serotonin Syndrome.

Clinically Significant Interactions

Interactions with other products primarily stem from the potential for additive effects or metabolic inhibition. Concomitant use with Serotonergic Agents, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and certain Triptans, can increase the risk of Serotonin Syndrome due to cumulative effects on serotonin levels. This combination warrants close medical supervision.

Other Documented Interactions

• CYP2D6 Inhibitors: Medications that inhibit the CYP2D6 enzyme, which metabolizes Dextromethorphan, may lead to increased concentrations of Dextromethorphan in the bloodstream. This pharmacokinetic interaction can increase the overall risk of adverse effects.
• Alcohol: Avoid consuming alcohol during treatment, as it can heighten the central nervous system effects of the medicine.

Delsym DM contains dextromethorphan complexed with polistirex resin, which serves as a sustained-release delivery vehicle for the active compound. Following systemic absorption, dextromethorphan is distributed to the central nervous system, where it acts as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and a sigma-1 (sigma1) receptor agonist.

At the NMDA receptor, which is an ionotropic glutamate receptor, dextromethorphan binds within the receptor ion channel, leading to blockade of ion flux. This antagonism modulates glutamatergic neurotransmission, specifically reducing neuronal excitability in the nucleus tractus solitarius (NTS) region of the brainstem, which functions as a central relay for pulmonary afferent vagal fibers. Concurrently, dextromethorphan functions as an agonist at the intracellular sigma1 receptor, which is localized at the mitochondria-associated endoplasmic reticulum membrane (MAM), modulating calcium signaling and cellular processes. The net system-level physiological consequence of these central actions is a pharmacodynamic modulation of the threshold for afferent sensory input required to initiate the cough reflex arc.

The administration of Delsym DM is standardized as an oral suspension. The product is classified as an extended-release preparation, utilizing Dextromethorphan Polistirex to control the rate of dissolution and provide sustained action over a defined dosing interval. The concentration is equivalent to 30 mg of Dextromethorphan Hydrobromide per 5 mL.

Dosing Regimen and Frequency

The standard regimen for individuals 12 years of age and older requires a single dose of 10 mL, which is administered every 12 hours. This specific twice-daily frequency is mandated to maintain the continuity of the extended-release profile. The total volume administered must not exceed 20 mL within any 24-hour period. The medicine is officially designated for short-term use and should not be continued for more than 7 days without professional medical consultation. The suspension may be taken with or without food as part of its general administration protocol.

Age Group	Single Dose (Every 12 Hours)	Maximum Dose (24 Hours)
Adults and Children ge 12 years	10 mL	20 mL
Children 6 to under 12 years	5 mL	10 mL
Children 4 to under 6 years	2.5 mL	5 mL
Children under 4 years	Do not use	Do not use

Administration Rules

For correct usage, the container must be shaken well immediately prior to measurement and administration. Dosing must be performed precisely using only the measuring cup provided with the product. The provided dosing cup is strictly intended for measuring this suspension and should not be used with other liquid products.

Research Evidence for Temporary Relief of Acute Cough

Dextromethorphan, the component in Delsym DM, was studied in research exploring short-term changes in acute, non-productive cough, which is often associated with acute or disruptive episodes of the common cold or upper respiratory tract infection (URTI). The primary evidence base comes from short-term randomized controlled trials (RCTs), and their data was evaluated in systematic reviews. These studies were evaluated in research exploring short-term symptom changes, where the treatment was observed in comparison against an inactive substance (placebo).

Research examined two main types of outcomes related to physical discomfort: objective measures and patient-reported outcomes. In controlled settings, studies monitored objective measures, such as cough counts. However, when researchers monitored patient-reported outcomes describing perceived discomfort, findings were mixed. Due to a high placebo effect that was observed in some studies involving acute cough, data show patterns related to symptom change that are often difficult to distinguish from the placebo effect alone. The regulatory status is based on a historical review of data related to its use for over-the-counter (OTC) purposes.

---

Studies Confirming the Extended-Release Formulation

The extended-release profile of the Polistirex technology was studied for its sustained action. The purpose of this formulation was evaluated in pharmacokinetic (PK) studies involving healthy adult volunteers. Research explored how the Polistirex formulation was associated with a prolonged plasma concentration profile. PK studies report observations of the duration of the medicine in the body compared to immediate-release liquids. These studies contribute to the broader evidence landscape by confirming the technical delivery of the drug.

---

Evidence in Special Age Groups

Clinical trials have been studied for populations experiencing conditions involving periods of heightened symptoms, including both adults and certain pediatric age groups. Certain pediatric age groups, generally those aged 6 to 11 years, were included in some studies. However, the evidence quality varies across studies when examining patient-reported outcomes in these younger populations. Systematic reviews often report that findings were mixed, and long-term effects are not fully established in pediatric patients. Therefore, data for certain groups remain insufficient to draw broad conclusions about clinical applicability.

Key Studies & References

1. Cough (acute): antimicrobial prescribing (NICE Guideline NG120, 2019) - Summary of the evidence
2. Dextromethorphan Pediatric Acute Cough Study (CHPA DXM) - ClinicalTrials.gov (NCT02651116)
3. Life-threatening pediatric dextromethorphan polistirex overdose (Used to infer Polistirex duration/PK profile)

Common questions about Delsym DM (FAQ)

Q: What is the purpose of Delsym DM?

A: Delsym DM is officially used to provide temporary relief from cough due to minor throat and bronchial irritation. The product is also indicated for the relief of nasal congestion and sneezing associated with the common cold and allergies. According to regulatory documents, its ingredients work to address these specific cold and allergy symptoms.

Q: How long does the relief from Delsym DM usually last?

A: Official product information indicates that Delsym DM is designed to provide relief that typically lasts for up to 12 hours. This duration is consistent with the product's extended-release formulation. This type of formulation is intended to provide long-lasting symptom relief from a single dose.

Q: Can I take Delsym DM if I have high blood pressure?

A: Regulatory documents advise that people who have heart disease or high blood pressure (hypertension) should consult a healthcare professional before using this product. This is because one of the active ingredients, phenylephrine, can potentially affect blood pressure and heart rate. Official product information advises that consultation with a professional is necessary to determine appropriateness based on existing medical conditions.

Q: What happens if I accidentally take more Delsym DM than recommended?

A: According to official safety information, taking more than the recommended amount, known as an overdose, can be very serious. An overdose may lead to nervousness, dizziness, sleeplessness, or severe side effects such as marked anxiety or hallucinations. If an overdose is suspected, official guidance strongly recommends seeking medical help or contacting a Poison Control Center immediately.

Q: Does Delsym DM contain ingredients that can cause drowsiness?

A: Yes, one of the active ingredients in Delsym DM is brompheniramine, which is an antihistamine. Antihistamines can cause drowsiness or sedation in some individuals. Due to this effect, official product labeling states that activities requiring alertness, such as driving a car or operating machinery, should be approached with caution until the user knows how the product affects them.

Q: Is Delsym DM safe to take before operating a vehicle?

A: Regulatory warnings state that due to the potential for impairment, the product should be used with caution before engaging in activities like driving or operating heavy machinery. This is because the product contains an antihistamine that may cause drowsiness or dizziness. This is an important safety consideration mentioned in the official product information.

How to Store and Dispose of Delsym DM

The official labeling for Delsym extended-release oral suspension dictates specific conditions to maintain the product's quality and ensure safety.

Storage Requirements

Delsym DM must be stored at Controlled Room Temperature, which is officially defined as a range between 20 C and 25 C (68 F and 77 F). The product must be protected from freezing and excessive heat to preserve the integrity of the liquid suspension. Store the product in its original container with the cap tightly closed.

Child-Safety and Disposal

The mandatory child-safety instruction on the label requires that the medicine be kept out of reach of children.

For disposal of unused or expired medicine, official guidance recommends using a drug take-back program. If a take-back program is unavailable, the product should not be flushed down a toilet or drain, but instead safely disposed of in household trash following regulatory recommendations.